Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 10/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 2/20 | 0.37 |
| ▸ | CDK8 | P49336 | 2/20 | 0.37 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | MAP2 | P11137 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21939131 | 0.85 | PKM (0.41) | SCN9ACHEK1EPHX2CLK1 | |
| SCHEMBL21939097 | 0.75 | TSHR (0.49) | PLK1CYP3A4IKBKB | |
| SCHEMBL21939107 | 0.74 | CDK8 (0.42) | PLK1CDK8CDK19IKBKB | |
| SCHEMBL12859094 | 0.72 | SCN9A (0.32) | SCN9A | |
| SCHEMBL20108363 | 0.70 | PLK1 (0.63) | CHEK1PLK1 | |
| SCHEMBL7965972 | 0.70 | IKBKB (0.42) | CYP2C9CYP3A4IKBKB | |
| SCHEMBL22067250 | 0.70 | PDE2A (0.37) | SCN9A | |
| SCHEMBL15943484 | 0.69 | IKBKB (0.50) | CDK8CDK19CYP2C9CYP3A4IKBKB | |
| SCHEMBL27398499 | 0.67 | F10 (0.41) | IKBKB | |
| SCHEMBL10252150 | 0.67 | MBOAT4 (0.45) | SCN9ACHEK1SLC6A2SLC6A4EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | disclosed |
| US-11325899-B2 | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-05-10 | — | — | US | disclosed |
| EP-3625223-B1 | PYRIMIDINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-08-11 | — | — | EP | disclosed |
| EP-3625222-B1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-21 | — | — | EP | disclosed |
| EP-3625228-B1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-07 | — | — | EP | disclosed |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-04-22 | — | — | US | disclosed |
| US-20210115031-A1 | BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-04-22 | — | — | US | disclosed |
| US-20200179383-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-06-11 | — | — | US | disclosed |
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | SCN9A 4332/4885CHEK1 3251/4885PLK1 4432/4885 |
| US-20200179383-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | SCN9A 4464/4885CHEK1 3217/4885PLK1 4410/4885 |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | SCN9A 4506/4885CHEK1 1854/4885PLK1 4022/4885 |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | SCN9A 4506/4885CHEK1 1854/4885PLK1 4022/4885 |
| US-20210115031-A1 | BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER4, PTGER1, PTGER2 | SCN9A 4282/4885CHEK1 3456/4885PLK1 4692/4885 |
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | PTGER1, PTGER4, PTGER2 | SCN9A 4618/4885CHEK1 1701/4885PLK1 4208/4885 |
| US-11325899-B2 | Benzofurane and benzothiophene derivatives as PGE2 receptor modulators | PTGER4, PTGER1, PTGER2 | SCN9A 4282/4885CHEK1 3456/4885PLK1 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.